Wurtman Richard
Massachusetts Institute of Technology, Department of Brain & Cognitive Sciences, 46-5023B, 43 Vassar Street, Cambridge, MA 02139, USA.
Expert Rev Neurother. 2006 Jul;6(7):957-64. doi: 10.1586/14737175.6.7.957.
Ramelteon, a potent agonist for the melatonin MT1 and MT2 brain receptors, has recently been granted approval by the US FDA for the treatment of insomnia associated with sleep onset. The drug has not exhibited potential for abuse or dependency in laboratory tests, nor does it interact with neurotransmitter receptors most associated with these phenomena, hence it has the great advantage of being a nonscheduled drug. Few data have been published in peer-reviewed journals describing its efficacy and side effects in patients with insomnia; however, side effects noted to date appear minor. No comparison study has been performed to determine whether the recommended dose of ramelteon 8 mg has any advantage over physiologic doses of melatonin (0.3 mg), particularly for long-term use.
雷美替胺是一种强效褪黑素MT1和MT2脑受体激动剂，最近已获得美国食品药品监督管理局（FDA）批准，用于治疗与入睡困难相关的失眠症。该药物在实验室测试中未表现出滥用或成瘾的可能性，也不与与这些现象最相关的神经递质受体相互作用，因此它具有作为非管制药物的巨大优势。同行评审期刊上发表的描述其对失眠患者疗效和副作用的数据很少；然而，迄今为止所注意到的副作用似乎较小。尚未进行比较研究以确定推荐剂量的8毫克雷美替胺是否比生理剂量的褪黑素（0.3毫克）具有任何优势，特别是对于长期使用而言。
